Anesthesiology and Pulmonary Medicine
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
June 30, 2011 2:33 am | by Bio-Medicine.Org | News | CommentsTOKYO, June 30, 2011 /- GLOW2 Study Shows NVA237 Provides Superior24-hour Bronchodilation to Placebo (p < 0.001) with Comparable Efficacy to Open-Label Tiotropium at 12 Weeks NVA237 Shown to be Well-Tolerated in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease...
Video Features World's First Essential Tremor Patient Treated With Noninvasive MR-Guided Focused Ultrasound
June 29, 2011 6:33 am | by Bio-Medicine.Org | News | CommentsCHARLOTTESVILLE, Va., June 29, 2011 /PRNewswire-USNewswire/ -- The last ten years have been challenging for Billy R. Williams of Fort Valley, Virginia. The former Pentagon employee, who survived the 9/11 terrorist attack, has suffered from essential tremor, a progressive and debilitating...
CardioFocus HeartLightâ„¢ Endoscopic Ablation System Enables Treatment of Atrial Fibrillation: Live Case and Abstract Presented at EHRA EUROPACE 2011
June 29, 2011 3:32 am | by Bio-Medicine.Org | News | CommentsMARLBOROUGH, Mass., June 29, 2011 /- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology was featured in a live case and scientific abstract presented at the...
Aeris Therapeutics names new CFO Carter
June 28, 2011 10:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsAeris Therapeutics LLC, a Woburn-based drug developer focused on treatments for emphysema and other advanced lung diseases, has appointed a new chief financial officer in Charles R. Carter.
Stanmore Receives US FDA Approval for its JTS Non-invasive Extendible Implant
June 24, 2011 7:33 am | by Bio-Medicine.Org | News | CommentsLONDON, June 24, 2011 /- Stanmore Implants ("Stanmore"), specialists in the design and manufacture of patient specific implants for complex orthopaedic reconstructions, announces that it has received US FDA 510k approval for its Juvenile Tumour System ("JTS") non-invasive...
Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
June 23, 2011 6:42 am | by Bio-Medicine.Org | News | CommentsGAITHERSBURG, Md., June 23, 2011 /- Sirnaomics, Inc. ( www.sirnaomics.com ) announced today that the company has signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., a Chinese pharmaceutical company trading on the Shenzhen Stock Exchange (SZSE: 002317). The...
AT & T to Wirelessly Connect Zephyr BioHarness
June 23, 2011 6:42 am | by Bio-Medicine.Org | News | CommentsDALLAS, June 23, 2011 /- AT&T * and Zephyr Technology today announced an agreement for AT&T to provide integrated wireless access to the next generation of the Zephyr BioHarness™ designed to measure critical vital signs, including ECG, heart rate, breathing rate, skin...
CardioFocus HeartLightâ„¢ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011
June 22, 2011 3:37 am | by Bio-Medicine.Org | News | CommentsMARLBOROUGH, Mass., June 22, 2011 /- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology will be the subject of several scientific sessions at the upcoming European Heart...
ERT to Present at the 2011 Wells Fargo Securities Healthcare Conference on June 23, 2011
June 17, 2011 6:32 am | by Bio-Medicine.Org | News | CommentsPHILADELPHIA, June 17, 2011 /- ERT (NASDAQ: ERT ), announced today that Keith Schneck, the Company's Chief Financial Officer, is scheduled to present at the 2011 Wells Fargo Securities Healthcare Conference at 1:30 PM ET on Thursday, June 23, 2011 in Boston. Interested...
Omnicell's OmniRx Automated Medication Dispensing System Receives 2011 Best in KLAS Award
June 16, 2011 11:33 am | by Bio-Medicine.Org | News | CommentsMOUNTAIN VIEW, Calif., June 16, 2011 /- Omnicell, Inc . (NASDAQ: OMCL ), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced the leading research firm, KLAS, has recognized Omnicell OmniRx ® automated...
PPTA Opposes Tax on Blood Clotting Factor
June 15, 2011 8:32 am | by Bio-Medicine.Org | News | CommentsANNAPOLIS, Md., June 15, 2011 /- PPTA opposes New Jersey Assembly Bill 2003 passed by the New Jersey Assembly Appropriations Committee on June 13 that imposes a new tax on therapies used to treat bleeding disorders like hemophilia. The bill creates The Bleeding Disorders Treatment Fund by...
North Shore-LIJ Health System Selects SIS Anesthesia
June 14, 2011 4:32 am | by Bio-Medicine.Org | News | CommentsATLANTA, June 14, 2011 /- Surgical Information Systems ("SIS"), a leader in perioperative information systems , announced that North Shore-LIJ Health System has extended its enterprise agreement with SIS by selecting SIS Anesthesia as its anesthesia documentation solution. The...
Guidelines for Ventilator Use Help Premature Infants Breathe Easier
June 12, 2011 8:33 pm | by Bio-Medicine.Org | News | CommentsBOSTON, June 13, 2011 /PRNewswire-USNewswire/ -- Guidelines that reduce the use of mechanical ventilation with premature infants in favor of a gentler form of respiratory support can profoundly affect those children's outcomes while reducing the cost of care, according to a team of...
Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
June 10, 2011 10:31 am | by Bio-Medicine.Org | News | CommentsBETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug...
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
June 10, 2011 8:33 am | by Bio-Medicine.Org | News | CommentsMONMOUTH JUNCTION, N.J., June 10, 2011 /- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE® (liposomal amikacin for inhalation) in...
GeNO LLC Announces New Patent for Nitric Oxide Delivery System
June 9, 2011 6:31 am | by Bio-Medicine.Org | News | CommentsCOCOA, Fla., June 9, 2011 /- GeNO LLC ( www.genollc.com ), a privately held, advanced development-stage technology company, today announced it has been awarded a new patent for its NITROSYL™ (Inhaled Nitric Oxide) Systems. U.S. Patent No. 7,947,227, GeNO's seventh patent,...
Mylan Receives Approval for Generic Version of Aricept® Tablets
June 7, 2011 12:33 pm | by Bio-Medicine.Org | News | CommentsPITTSBURGH, June 7, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride (HCl) Tablets, 5...
Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
June 6, 2011 5:33 pm | by Bio-Medicine.Org | News | CommentsCHICAGO and SAN DIEGO, June 6, 2011 /- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01) in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected...
Crux Successfully Completes Funding for Advanced Filter for PE Prevention
June 6, 2011 2:34 pm | by Bio-Medicine.Org | News | CommentsMENLO PARK, Calif., June 6, 2011 /- Crux Biomedical Inc., a developer of an advanced implantable vena cava filter (VCF), announced the successful completion a $12.0MM investment round. The round was led by Three Arch Partners, which was joined by current investors, Alloy Ventures...
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
June 6, 2011 3:33 am | by Bio-Medicine.Org | News | CommentsSILVER SPRING, Md., June 6, 2011 /- United Therapeutics Corporation (NASDAQ: UTHR ) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic...
New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
June 5, 2011 5:31 am | by Bio-Medicine.Org | News | CommentsINDIANAPOLIS, June 5, 2011 /- Eli Lilly and Company (NYSE: LLY ) announced today that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is...
Mylan Receives Approval for Generic Version of Effexor XR® Capsules
June 2, 2011 9:32 am | by Bio-Medicine.Org | News | CommentsPITTSBURGH, June 2, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl)...
Commencement of GMP Production Project for Lead Anti-Cancer Product PAT-LM1
June 2, 2011 9:32 am | by Bio-Medicine.Org | News | CommentsMELBOURNE, Australia and PRINCETON, N.J., June 2, 2011 /- Patrys Limited (ASX: PAB) (the "Company"), a biopharmaceutical company focused on the development of novel treatments for cancer, is pleased to announce it has extended its relationship with Laureate Biopharmaceutical Services,...
Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
June 2, 2011 6:32 am | by Bio-Medicine.Org | News | CommentsNEW YORK, June 2, 2011 /- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development. Over the...
Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
June 2, 2011 5:32 am | by Bio-Medicine.Org | News | CommentsWALTHAM, Mass., June 2, 2011 /- Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)-...
